Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI363 neoadjuvant therapy in resectable stage II–III non-small cell lung cancer
CTR20260180Phase 2Active
- Sponsor
- InnoCare Pharma
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IBI363 in non-small cell lung cancer (NSCLC), sponsored by InnoCare Pharma. Started Jan 2026; status: active.
02
Drugs
IBI363
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20260180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260180.